D-0673-2026 Class II Ongoing
FDA drug recall D-0673-2026 was initiated by Reliance Life Sciences Private Limited on Jun 24, 2026 and is designated Class II. Reason for recall: Lack of Sterility Assurance The recall status is ongoing. Affected quantity: 11,400 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 15, 2026
- Initiation Date
- Jun 24, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 11,400 vials
Product description
Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873. NDC: 70069-0836-01
Reason for recall
Lack of Sterility Assurance
Distribution pattern
Nationwide in the USA
Code information
Lot, expiry: RBIH0125A Jan 31, 2028; RBIH0225A Feb 29, 2028; RBIH0325A Feb 29, 2028; RBIH0525A Mar 31, 2028
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0673-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026